Form 4: Neogenomics Executive Greg D. Aunan Reports Stock Transactions

Chief Accounting Officer Greg D. Aunan reports acquisition and disposal of Neogenomics stock and derivative securities.

Summary

• On May 1, 2024, Greg D. Aunan, Chief Accounting Officer of Neogenomics Inc., surrendered 937 shares of common stock to satisfy tax obligations related to the vesting of restricted stock.
• Following this transaction, Aunan directly owns 14,453 shares of Neogenomics common stock.
• On May 1, 2023, Aunan was granted 28,662 stock options with an exercise price of $14.62, vesting ratably over four years.
• On May 2, 2024, Aunan was granted 26,978 stock options with an exercise price of $13.96, vesting ratably over three years.
• Also on May 2, 2024, Aunan was granted 16,117 restricted stock units, vesting ratably over three years.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive, which is a routine activity.

Positives

• The granting of stock options and restricted stock units to a key executive suggests an incentive alignment with the company's long-term performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions reported may be of interest to shareholders as they provide insight into executive compensation and ownership.

Key Dates